What Next: TBD | Tech, power, and the future

To keep places like Phoenix habitable, we need to have air-conditioning. But to have air-conditioning, we need a functional, modern electrical grid. With America’s grid already aging—and more demand coming in the form of electric cars and more A/C for hotter weather—what will it take to keep it going as the weather gets more extreme? Guest: Dr. Joshua Rhodes, research scientist at the University of Texas at Austin studying energy systems and how they interact with our environment, climate, and life.If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.

Pedestrian deaths in America have been rising for the last decade, while dropping in Europe and Japan. What makes the U.S. so dangerous for pedestrians?Guest: Jessie Singer, author of There Are No Accidents: The Deadly Rise of Injury and Disaster―Who Profits and Who Pays the Price.  Hosted on Acast. See acast.com/privacy for more information.

Contract negotiations between the Teamsters and UPS broke down last week and now a strike looms. With time running out, can both sides reach a deal? Guest: Noam Scheiber, labor reporter for the New York Times.If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.

Andrew Tate’s gross mix of self-help, toxic masculinity and misogyny captured the minds of young boys on the internet. It also led to indictments in Romania on human trafficking and rape charges.  Guest: Lisa Miller, contributing editor at New York magazine.If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.

It seems like with each new Musk innovation, a new Twitter replacement appears in response. But Threads is backed by Meta and available in just a few clicks for an Instagram user. Could it be the one?Guest: Mike Isaac, technology reporter for the New York Times.If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.

Even if you like the convenience of your phone unlocking after it reads your face, there are reasons to be wary of the TSA bringing facial recognition technology to the airport. Guest: Geoffrey Fowler, technology columnist for the Washington Post.If you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.

A shortage of basic chemotherapy drugs to treat cancer is jeopardizing the care of hundreds of thousands of patients. The drugs aren’t expensive, or patented—so where are they? Guest: Ed Yong, science journalist at The Atlantic.Host: Lizzie O'LearyIf you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.

Semaglutide, better known by its brand name Ozempic, has been making headlines as a weight loss drug – despite only having FDA approval to treat diabetes. Now, some say it doesn’t just quell cravings for food – it helps quiet cravings for alcohol, drugs, and other compulsive behaviors. For years, researchers have been studying semaglutide's effectiveness as an addiction cure in animals. What have they found? And – does it actually work? Guest: Sarah Zhang covers health and medicine for The AtlanticIf you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Amicus—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.

On Wednesday, the Federal Trade Commission sued Amazon, accusing the online giant of “tricking and trapping people into recurring subscriptions.” The complaint says Amazon “knowingly duped millions of consumers into unknowingly enrolling in Amazon Prime." With murmurs of a larger antitrust probe against Amazon just around the corner, how serious is this suit for the tech giant? Guest: Leah Nylen, antitrust reporter at BloombergIf you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Amicus—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.

One son was preparing to take over George Soros’s multi-billion-dollar empire. Then, there was a falling out, and a new heir-apparent was chosen. Who is Alex Soros? And, as he takes over for one of the most influential figures in American politics, what can we expect from him? Guest: Gregory Zuckerman, special writer at the Wall Street JournalHost: Emily PeckIf you enjoy this show, please consider signing up for Slate Plus. Slate Plus members get benefits like zero ads on any Slate podcast, bonus episodes of shows like Slow Burn and Dear Prudence—and you’ll be supporting the work we do here on What Next TBD. Sign up now at slate.com/whatnextplus to help support our work. Hosted on Acast. See acast.com/privacy for more information.